Floatz logo

Casopitant

Nausea and Vomiting, Chemotherapy-Induced

GlaxoSmithKlineSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nausea and Vomiting, Chemotherapy-Induced cohort.

Asset / SponsorPhaseRating
Zofran
Jiuda Zhao
Phase 3B

Same molecule, other indications

Casopitant is also rated in:

chemotherapy-induced toxicityDormant
BB
Indicative ·
64 / 100
View asset →
major depressive disorderDormant
B
Indicative ·
60 / 100
View asset →
Nausea and VomitingDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →